DOP2015000214A - Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a - Google Patents

Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a

Info

Publication number
DOP2015000214A
DOP2015000214A DO2015000214A DO2015000214A DOP2015000214A DO P2015000214 A DOP2015000214 A DO P2015000214A DO 2015000214 A DO2015000214 A DO 2015000214A DO 2015000214 A DO2015000214 A DO 2015000214A DO P2015000214 A DOP2015000214 A DO P2015000214A
Authority
DO
Dominican Republic
Prior art keywords
formula
disorders
compounds
type
oxides
Prior art date
Application number
DO2015000214A
Other languages
English (en)
Inventor
Karla Drescher
Michael Ochse
Katja Jantos
Jürgen Dinges
Hervé Geneste
Jayne Froggett
Clarissa Jakob
Original Assignee
Abbvie Inc
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50241454&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2015000214(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc, Abbvie Deutschland filed Critical Abbvie Inc
Publication of DOP2015000214A publication Critical patent/DOP2015000214A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

COMPUESTOS DE LA FÓRMULA I, LOS N-ÓXIDOS, TAUTÓMEROS, LAS PRODROGAS Y LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS: (I) EN FÓRMULA I LA VARIABLE X1 ES CH O N, X2 ES O O S, Y R1, R2, R3, R4 Y Q SON SEGÚN SE LOS DEFINIÓ EN LAS REIVINDICACIONES. LOS COMPUESTOS DE LA FÓRMULA I, LOS N-ÓXIDOS, TAUTÓMEROS, LAS PRODROGAS Y LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS SON INHIBIDORES DE LA FOSFODIESTERASA DEL TIPO 10A. POR LO TANTO, LA INVENCIÓN TAMBIÉN SE REFIERE AL USO DE LOS COMPUESTOS DE LA FÓRMULA I, LOS N-ÓXIDOS, TAUTÓMEROS, LAS PRODROGAS Y LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS PARA LA FABRICACIÓN DE UN MEDICAMENTO Y QUE POR LO TANTO SON APROPIADOS PARA TRATAR O CONTROLAR TRASTORNOS MÉDICOS QUE SE SELECCIONAN ENTRE: TRASTORNOS NEUROLÓGICOS Y TRASTORNOS PSIQUIÁTRICOS, PARA MEJORAR LOS SÍNTOMAS ASOCIADOS CON DICHOS TRASTORNOS Y PARA REDUCIR EL RIESGO DE DICHOS TRASTORNOS. FÓRMULA I
DO2015000214A 2013-03-13 2015-09-03 Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a DOP2015000214A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361779141P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
DOP2015000214A true DOP2015000214A (es) 2015-12-31

Family

ID=50241454

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2015000214A DOP2015000214A (es) 2013-03-13 2015-09-03 Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a

Country Status (22)

Country Link
US (1) US9200005B2 (es)
EP (1) EP2970328B1 (es)
JP (1) JP2016510786A (es)
KR (1) KR20150127724A (es)
CN (1) CN105358561A (es)
AR (1) AR095267A1 (es)
AU (1) AU2014230825A1 (es)
BR (1) BR112015022094A2 (es)
CA (1) CA2902654A1 (es)
CL (1) CL2015002545A1 (es)
CR (1) CR20150496A (es)
DO (1) DOP2015000214A (es)
HK (1) HK1219273A1 (es)
IL (1) IL240593A0 (es)
MX (1) MX2015012389A (es)
PE (1) PE20160040A1 (es)
PH (1) PH12015501962A1 (es)
RU (1) RU2015143536A (es)
SG (1) SG11201507380PA (es)
TW (1) TW201441230A (es)
UY (1) UY35393A (es)
WO (1) WO2014140086A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CN107074824B (zh) * 2014-09-05 2021-01-08 基因泰克公司 作为用于治疗癌症的pcaf和gcn5抑制剂的式(i)的酞嗪衍生物
WO2016036873A1 (en) 2014-09-05 2016-03-10 Genentech, Inc. Therapeutic compounds and uses thereof
CN107406429B (zh) 2015-01-09 2021-07-06 基因泰克公司 哒嗪酮衍生物及其在治疗癌症中的用途
CN111182898B (zh) * 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN115838364A (zh) * 2022-12-20 2023-03-24 河南沁朋科技有限公司 一种3,3-双噻吩的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001603T2 (tr) * 1997-12-05 2000-10-23 Astrazeneca Uk Limited Yeni bileşikler
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
WO2005120514A1 (en) 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
CA2578996A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
WO2007022280A1 (en) 2005-08-16 2007-02-22 Memory Pharmaceuticals Corporation Phosphodiesterase 10 inhibitors
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
WO2007082546A1 (en) 2006-01-20 2007-07-26 H. Lundbeck A/S Use of tofisopam as a pde10a inhibitor
BRPI0707223A2 (pt) 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
JP2009527560A (ja) 2006-02-21 2009-07-30 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体
WO2007098214A1 (en) 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
EP1996587A1 (en) 2006-02-23 2008-12-03 Pfizer Products Incorporated Substituted quinazolines as pde10 inhibitors
EP1991531A1 (en) 2006-02-28 2008-11-19 Amgen Inc. Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors
US20070265258A1 (en) 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
AU2007223801A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
WO2008001182A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
EP2057153B1 (en) 2006-07-10 2012-09-12 H. Lundbeck A/S (3-aryl-piperazin-1-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2009025823A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
US20090062291A1 (en) 2007-08-22 2009-03-05 Essa Hu Phosphodiesterase 10 inhibitors
US20090054434A1 (en) 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
TW200918519A (en) 2007-09-19 2009-05-01 Lundbeck & Co As H Cyanoisoquinoline
US20090143361A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
US20090143392A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Methods of Treating Obesity and Metabolic Disorders
US20090143391A1 (en) 2007-11-30 2009-06-04 Norbert Hofgen Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10
KR20100110804A (ko) 2007-11-30 2010-10-13 와이어쓰 엘엘씨 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진
WO2009076454A2 (en) * 2007-12-12 2009-06-18 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2011024873A1 (ja) * 2009-08-26 2011-03-03 武田薬品工業株式会社 縮合複素環誘導体およびその用途
EP2632461A4 (en) 2010-10-29 2014-04-02 Merck Sharp & Dohme ISOINDOLINONE COMPOUNDS USEFUL AS PDE INHIBITORS 10
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a

Also Published As

Publication number Publication date
PH12015501962A1 (en) 2016-01-11
SG11201507380PA (en) 2015-10-29
BR112015022094A2 (pt) 2018-06-12
AR095267A1 (es) 2015-09-30
EP2970328B1 (en) 2017-04-26
PE20160040A1 (es) 2016-02-11
CN105358561A (zh) 2016-02-24
IL240593A0 (en) 2015-09-24
UY35393A (es) 2014-10-31
US20140275069A1 (en) 2014-09-18
JP2016510786A (ja) 2016-04-11
HK1219273A1 (zh) 2017-03-31
WO2014140086A1 (en) 2014-09-18
CA2902654A1 (en) 2014-09-18
AU2014230825A1 (en) 2015-09-03
RU2015143536A (ru) 2017-04-18
TW201441230A (zh) 2014-11-01
CR20150496A (es) 2016-02-19
MX2015012389A (es) 2016-03-03
KR20150127724A (ko) 2015-11-17
CL2015002545A1 (es) 2016-07-22
EP2970328A1 (en) 2016-01-20
US9200005B2 (en) 2015-12-01

Similar Documents

Publication Publication Date Title
DOP2015000214A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
CR20150633A (es) Derivados del bipirazol como inhibidores jak
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
GT201400089A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
EA201891050A1 (ru) Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
MX2016012451A (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina.
MX2017009288A (es) Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3.
UY35746A (es) Derivados de fenilalanina sustituidos
TR201819805T4 (tr) Flavaglin türevleri̇.
AR084051A1 (es) Derivados de 1-hidroxi-2-oxo-hidroquinolina, composiciones farmaceuticas que los contienen y uso de los mismos para tratar deficits cognitivos asociados con esquizofrenia y otros trastornos psiquiatricos y/o neurologicos
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
CR20150092A (es) Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad del reflujo
ECSP18056196A (es) Derivados de indano